The previous sub-classifications identified the ccrcc4 (Beuselinck et al.), like Cluster 4 established by Hakimi et al. in the COMPARZ trial (108), as an inflamed subtype with moderate angiogenesis, but high immune infiltration, PD-L1 expression on tumor cells by IHC, and poor response to VEGFRi. Here, CD274 is linked to neoplasm.